Table 2.

Quality Assessment Scoring of Studies

	Selection			Comparability of group		Outcome
Reference	1	2	3	4	5	6	7	Total
HUR et al (2008)	*	*	*	*	**			6
DU et al (2009)	*	*	*	*	**	*		7
Huang et al (2010)	*	*	*	*	*	*		6
Cai et al (2011)	*	*	*	**	**	*		8
Scatizzi et al (2011)	*	*	*	**	**	*		8
Shuang et al (2011)	*	*	*	**	*	*		7
Chen et al (2012)	*	*	*	**	**	*		8
Hamabe et al (2012)	*	*	*	*	**		*	7
Kim et al (2013)	*	*	*	**	**			7
Lin et al (2013)	*	*	*	**	**	*		8
Shinohara et al (2013)	*	*	*	**	*	*		7

Quality was assessed using a star scoring system. Selection for treatment: 1, inclusion criteria reported; 2, representability of patients undergoing LAG with D2 lymph node dissection to population undergoing surgery for AGC; 3, representability of patients undergoing OG with D2 lymph node dissection to population undergoing surgery for AGC. Comparability of groups (if yes to all, 2 stars; if one of these characteristics was not reported, 1 star; if the two groups differed, no star): 4, age, sex, and body mass index (BMI); 5, tumor site, tumor histological type, tumor size, and tumor stage. Outcome assessment: 8, > 8 outcomes clearly recorded, 1 star; 9, quality of follow-up, 1 star if > 90 patients were followed up for five years.